Portland State University

PDXScholar
Systems Science Faculty Publications and
Presentations

Systems Science

12-2014

Data Sources Regarding the Nonmedical Use of
Pharmaceutical Opioids in the United States
Teresa D. Schmidt
Portland State University

Amanuel Zimam
Portland State University

Alexandra Nielsen
Portland State University

Wayne Wakeland
Portland State University, wakeland@pdx.edu

Follow this and additional works at: https://pdxscholar.library.pdx.edu/sysc_fac
Part of the Chemicals and Drugs Commons

Let us know how access to this document benefits you.
Citation Details
Schmidt, Teresa D.; Zimam, Amanuel; Nielsen, Alexandra; and Wakeland, Wayne, "Data Sources Regarding
the Nonmedical Use of Pharmaceutical Opioids in the United States" (2014). Systems Science Faculty
Publications and Presentations. 20.
https://pdxscholar.library.pdx.edu/sysc_fac/20

This Post-Print is brought to you for free and open access. It has been accepted for inclusion in Systems Science
Faculty Publications and Presentations by an authorized administrator of PDXScholar. Please contact us if we can
make this document more accessible: pdxscholar@pdx.edu.

NIH-PA Author Manuscript

Published in final edited form as:
Rev Health Care. 2014 ; 5(1): 33–50. doi:10.7175/rhc.v5i1.883.

Data Sources Regarding the Nonmedical Use of Pharmaceutical
Opioids in the United States
Teresa Schmidt, MS [Research Associate]
Systems Science Graduate Program Portland State University
Amanuel Zimam, MBA [Research Associate]
Systems Science Graduate Program Portland State University
Alexandra Nielsen, BS [Research Associate]
Systems Science Graduate Program Portland State University

NIH-PA Author Manuscript

Wayne Wakeland, PhD [Associate Professor]
Systems Science Graduate Program Portland State University

Abstract
Objective—Recent increases in the nonmedical use of pharmaceutical opioids and the adverse
outcomes associated with them have stimulated a large amount of research and data collection on
this public health problem. Systematic organization of the available data sources is needed to
facilitate ongoing research, analysis, and evaluation. This work offers a systematic categorization
of data sources regarding the nonmedical use of pharmaceutical opioids in the United States.
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Methods—A list of keywords regarding the nonmedical use of pharmaceutical opioids was used
to conduct systematic searches in PubMed®. Filtration of search results generated 92 peerreviewed academic articles, published between January 1995 and April 2012, as well as a number
of primary data sources. Lists of topics were developed independently by two researchers which
were later compared and consolidated. All sources were then categorized according to their
relevance to each of these topics and according to their capacity for geographical and longitudinal
trend analysis.
Results—Tables cataloging data sources can be used to identify data relevant to specific topics
in diversion, nonmedical use, and adverse outcomes associated with pharmaceutical opioids, and
they illustrate global trends in data coverage, identifying several topics that have minimal data. A
network diagram illustrates global trends in data coverage, showing variation among sources in
the number of topics they cover, as well as variation among topics in the number of sources that
cover them.
Correspondence to: Teresa D. Schmidt tds@pdx.edu Phone: 503-725-4960 tel Fax: 503-725-8489 fax.
Disclosures: The authors report no conflicts of interest.
Directions for Further Research Researchers, policymakers, and other professionals in the health care field are encouraged to refer
to the tables in this article when identifying data sources for ongoing research, analysis, and evaluation of this public health problem.
In addition, data collection efforts are needed to address several topics that appear to have few data sources covering them, including
nonmedical use frequency, addiction relapse, polydrug use, availability of pharmaceutical opioids for nonmedical use, domestic
impact, and transaction tracking. With relatively few data sources identified, measurement of these topics would likely be beneficial
for understanding and ameliorating the diversion, nonmedical use, and adverse outcomes associated with pharmaceutical opioids in
the United States.
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Conclusions—The categorization of data sources is hoped to facilitate ongoing research,
analysis, and evaluation of this public health problem by serving as a guide for researchers, policy
makers, and others who seek data regarding the nonmedical use of pharmaceutical opioids in the
United States.
Keywords
nonmedical use; diversion; adverse outcomes; pharmaceutical opioids; data sources
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A dramatic rise in the nonmedical use of pharmaceutical opioids presents the United States
with a substantial public health problem [1]. The 2011 National Survey of Drug Use and
Health (NSDUH) estimates that 2.3 percent of the US population used pain relievers
nonmedically during the past month, and that at least 1.9 million individuals have initiated
nonmedical use each year since 2002 [2]. Such medications are now among the most
popular drugs for nonmedical use, second only to marijuana [3], and are associated with a
variety of adverse outcomes. The number of overdose deaths involving opioids increased
threefold between 1999 and 2006, and fivefold among youth aged 15 to 24 [4]. Use
disorders involving pain reliever abuse or dependence were estimated to afflict 1.4 million
individuals in 2011, one third of whom were young adults between the ages of 18 and 25
[2]. Many of the pharmaceutical opioids that are used nonmedically are diverted in some
way from their legally intended purpose: Over half of nonmedical users report acquiring
their most recent supply of pain relievers from a friend or relative, and among them, over
three quarters report that their friend or relative had acquired the pain relievers from a doctor
[2], [5].
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Considerable research has been conducted on the public health problems surrounding
nonmedical use of pharmaceutical opioids. Large scale primary data collection methods,
such as the NSDUH, the National Poison Data System (NPDS), and the Drug Abuse
Warning Network (DAWN) have enabled a large number of analyses on the prevalence [6],
[7], characteristics [8], [9], and adverse outcomes [10], [11] associated with nonmedical
opioid use. Smaller, independent studies have measured prevalence among a number of
prominent subpopulations, such as physicians [12], anesthesiologists [13], and student
pharmacists [14], and have been instrumental in identifying additional factors that are
relevant to this public health problem. These factors include polydrug use [15], mental
health problems [16], social support [17], and routes of diversion [18].
Because of the large number of data sources available for studying nonmedical opioid use
and the wide range of relevant factors, systematic organization of data sources is needed to
facilitate ongoing research, analysis, and evaluation of this public health problem. Initial
efforts organize data sources according to topic [19] and geographical scale [20], however a
systematic approach has not yet been employed in the search and categorization of existing
data sources. This work provides a systematic approach to the collection and categorization
of data sources along a set of prominent topics in the field, providing a guide for researchers,
policy-makers, and others who seek data on various aspects of the nonmedical use of
pharmaceutical opioids in the United States.
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This work was conducted to advance a larger research project which uses System Dynamics
modeling to investigate the nonmedical use of pharmaceutical opioids in the United States.
System Dynamics is a computer simulation methodology that describes a system in terms of
stocks and flows which are governed by differential equations [21], [22]. This methodology
is capable of incorporating a large range of available data into a systems-level model that
represents the global dynamics of the system of interest [23].
Keyword Searches
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To provide empirical support for the specification of a System Dynamics model, data
sources were systematically sought out for their relevance to the diversion, nonmedical use,
and adverse outcomes associated with pharmaceutical opioids in the United States. This
investigation began with a list of keywords which were identified from the project's
previously established collection of electronic resources, including journal articles,
government documents, and reports regarding the public health problem of nonmedical
opioid use. The list was compiled by scanning through documents for words listed in a
“keywords” field, and was then simplified by omitting keywords of non-opioid drugs and
substances, specific drug formulation names (e.g., Fentanyl, OxyContin), words pertaining
specifically to medical treatment, and other words that were not directly related to the
phenomena of interest (e.g., screening instrument, prevention, mental health, triplicates).
The final list of keywords was grouped into diversion, nonmedical use, and adverse outcome
categories, and used in three PubMed searches for peer-reviewed academic articles
published between January 1, 1995, and May 1, 2012. The specific searches, submitted to
PubMed® in May of 2012, are included in Table 1.
Source Filtration
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Literature searches conducted in PubMed® returned a large number of hits regarding
diversion (1,506), nonmedical use (15,512), and adverse outcomes (4,508). These studies
were filtered by a team of three graduate students with the following search criteria: All
journal articles were required to be peer reviewed, to be available in the English language, to
contain quantitative data on human subjects, to have a minimum sample size of 30
participants, and to have direct relevance to the US population. Studies on medical treatment
with pharmaceutical opioids were excluded, including treatment for opioid or opiate
dependence. Articles which analyzed secondary data were also excluded, but the primary
data sources used were noted for inclusion in the categorization process described below.
A filtered collection of 92 articles meeting the search criteria were evaluated qualitatively by
two graduate students, who independently created lists of the most prominent topics. The
two lists were compared, and differences between them were resolved through discussion,
resulting in a final list of 20 topics. These topics were grouped for their relevance to
diversion, nonmedical use, and adverse outcomes, as they appear in Tables 2 through 4. At a
later time point, two design features were identified as salient, as several articles reported
analyses of longitudinal and/or geographic trends. These attributes are included in the
Appendix.
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Categorization
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A list of sources was created, including the 92 filtered articles and 42 additional primary
sources that had been noted during the filtration process. Each source was categorized by the
geographical scale at which it was collected, and for its relevance to any of the 20 topics and
2 design attributes. Closer examination of articles during this phase resulted in several more
instances of exclusion, for reasons of confounding (e.g., opioids with heroin; nonmedical
with medical use), absence of original data (e.g., review articles, secondary analyses), or
research on excluded topics (e.g., search algorithms for post-marketing surveillance,
healthcare costs among nonmedical users). Several primary sources were also excluded
during the categorization phase, for reasons of duplication (e.g., Veterans Affairs and
Veterans Health Administration), and measurement of excluded topics (e.g., adverse events,
which imply medical use). This resulted in a final list of 35 original research articles as well
as 22 primary data sources, categorized in Tables 2 through 4, and the Appendix. For
primary data sources (i.e., those not specific to any journal article), additional references
were sought to establish whether they satisfied each scale, topic, and attribute in the tables.

Results
NIH-PA Author Manuscript

The following sections describe the data sources that were found to be relevant to various
aspects of diversion, nonmedical use, and the adverse outcomes associated with
pharmaceutical opioids, as shown in Tables 2 through 4. Data sources' capacity for
geographical and longitudinal trend analysis will not be discussed in detail, but results are
available in the Appendix. In all tables, row headings indicate prominent topics, while
column headings indicate the highest scale at which the data source is relevant. Sources are
arranged by bullets within a table cell to differentiate large scale primary sources from
independent studies. Bullets containing the name of a primary source are followed by
informational resources and example analyses. Bullets without a source name contain the
independent studies that have been conducted for a given topic and scale level. Sources that
can be accessed publicly are indicated with bold type font, and sources that do not strictly
limit responses to pharmaceutical opioids, but imply them (e.g., listing “pain killers,” “pain
relievers,” or “narcotics other than heroin”) are indicated with an asterisk. Key highlights
among the predominant data sources for nonmedical use, diversion, and adverse outcomes
are provided in the sections below.
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Nonmedical Use Table
Table 2 categorizes data sources by central topics in the prevalence, frequency, and
characteristics of those who use pharmaceutical opioids nonmedically in the United States.
Because of the illegal nature of nonmedical opioid use, its prevalence is measured most
often through self-report surveys, especially among non-patient populations [24], [25], [26],
[27], [28], [29], [30], [31]. Among patient populations, prevalence of nonmedical use is
measured with either survey [16], [24], [32] or toxicology methods, such as urine screening
[24], [33], [34]. In addition to prevalence, some surveys ask about the frequency of
nonmedical use during a recent period of time [26], [35], [36], [37], [38], [39], [40], or about
the age of initiation [5], [41], [42] or duration [43] of nonmedical use. Other studies measure
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prevalence among more specific populations, such as parturients [44], club goers [36],
student pharmacists [14], healthcare workers [12], [13], and probationers [17].
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A great amount of attention is paid to determining the characteristics of nonmedical opioid
users [8], [45], [46]. Not surprisingly, a large number of data sources capture demographic
information, which allows nonmedical use of pharmaceutical opioids to be studied in terms
of age, gender, and racial/ethnic differences. Additional characteristics include income [42],
[47], employment status [27], [28], [42], [47], [48], housing status [42], [48], educational
performance [46] and attainment [16], physical health [16], [30], [31], [47], mental health
[16], [17], [30], [31], [32], [34], [46], and legal or behavioral problems [34], [42], [47].
Social characteristics include marital status [16], [27], [28], [49], family structure [27], [28],
[49], social support [17], urbanicity [50] and community size [9], as well as college-level
characteristics [51]. Several studies have also measured motivations for nonmedical use,
such as pain relief, experimentation, or “getting high” [9], [14], [24], [37], [38], [52], as well
as attitudes about the perceived risk of using pharmaceutical opioids nonmedically [9]. Two
additional topics of importance include common routes of administration [9], [13], [37],
[38], [48], [53], [54], [55], [56], [57] and polydrug use behaviors [5], [13], [15], [29], [35],
[38], [42], [43], [58], [59] which make the potential harm of nonmedical use especially high
[43].
Diversion Table
Table 3 provides categorization of sources based on their relevance to the diversion of
pharmaceutical opioids. Diversion is defined as the transfer of pharmaceutical opioids from
their lawful purpose to illicit use [60]. The manufacturing and delivery of pharmaceutical
opioids to retail locations is monitored by the Drug Enforcement Agency (DEA) through the
Automation of Reports and Consolidated Orders System (ARCOS) [61]. Various routes of
diversion can disrupt the supply chain of pharmaceutical opioids between their production
and lawful distribution to patients. Large scale thefts are recorded by the DEA [62], [63] and
diversion by healthcare workers is captured in police records [64], through the RADARS®
key informant network [65], and in independent studies [18], [66].
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Other routes of diversion can be measured through self-reports of individuals who have
acquired pharmaceutical opioids through illicit means. Monitoring the Future [39], [67] the
National Survey of Drug Use and Health (NSDUH) [68], [69], [70], the National Addictions
Vigilance Intervention and Prevention Program (NAVIPPRO) [57], and the Delaware
School Survey [30], [31] all ask respondents questions regarding the source of nonmedically
used pharmaceutical opioids. Diversion can also be measured indirectly by asking
respondents whether they believe pharmaceutical opioids could be easily acquired for
nonmedical use [9], [30], [31], and through post-marketing surveillance techniques such as
monitoring online forums [71] and measuring the prevalence of accidental poisonings [5],
[10], [72], [73], [74] and substance abuse treatment [43], [57], [75].
Adverse Outcomes Table
Table 4 categorizes data on a variety of adverse outcomes associated with pharmaceutical
opioids. Topics included in this table are not meant to imply causal relationships, but
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indicate a variety of negative outcomes that have been found to be associated with
nonmedical opioid use, such as fatal and nonfatal opioid poisonings, substance use
disorders, addiction relapse, violence and suicide. A common measurement for many of
these adverse outcomes is the International Classification of Diseases (ICD-10) [76], which
contains medical codes for opioid dependence, opioid abuse, and unintentional poisonings
due to methadone, heroin, or “other opioids.” These codes are the basis for much of the data
collected through hospital medical records [77], [78], [79], insurance claims [79], and death
certificates which indicate instances where unintentional opioid poisoning was recorded as
the primary cause of death [80], [81]. Data regarding emergency department visits for
nonfatal opioid poisonings can be accessed through the Drug Abuse Warning Network
(DAWN) [82], and data regarding fatal opioid poisonings are available through the CDC's
National Vital Statistics System (NVSS) [83].
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Other common measurements of adverse outcomes include those gathered by poison call
centers, treatment centers, and surveys. The National Poison Data System (NPDS) [84] is a
prominent national data source for nonfatal opioid poisonings, collecting data from 57
poison call centers throughout the United States. Information regarding the prevalence of
opioid use disorders [43], [57], [85] as well as addiction relapse [12], [57] are captured by
substance abuse treatment centers, such as those monitored by the National Addictions
Vigilance Intervention and Prevention Program (NAVIPPRO®) [86]. Several questions on
the NSDUH can also be used to determine whether participants have opioid dependence
[40], [47], [68], and independent studies have used surveys to measure outcomes such as
dependence and withdrawal symptoms [26], [30], [35], [38], and witnessing or experiencing
an overdose [17].

Discussion
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The categorization of data sources in Tables 2 through 4 can serve as a guide for those who
seek data sources regarding the diversion, nonmedical use, and adverse outcomes associated
with pharmaceutical opioids in the United States. Global trends in data source coverage are
illustrated as a bi-partite network in Figure 1. Topics from Tables 2 through 4 are listed on
the left, and primary data sources are listed on the right. Connections indicate coverage of
topics by data sources, illustrating (1) variety among sources in the number of topics they
cover, as well as (2) variety among topics in the number of sources that cover them. The
topical coverage of each source is shown by the number of connections that stem from it.
Large scale sources such as NAVIPPRO, RADARS, MTF, and DAWN collect data that is
relevant for many topics within the pharmaceutical opioid public health problem. Other
sources in this review, such as the National Inpatient Survey (NIS), Automation of Reports
and Consolidated Orders System (ARCOS), the American College of Medical Toxicology
(ACMT), and Veterans Affairs (VA) Medical records, are relevant to only one topic.
In a similar manner, the source coverage of each topic is shown by the number of
connections that lead to it. Some topics are covered by more data sources than others. More
than half of the primary sources contain data regarding individual characteristics of those
exhibiting behaviors of nonmedical use of pharmaceutical opioids. Many sources also cover
prevalence, opioid use disorders, illicit sources, social characteristics, and routes of
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administration. By contrast, addiction relapse, domestic impact, and transaction tracking
were each covered by only one primary data source. The scarcity of sources covering some
topical areas may be due to sufficiency of a single source, such as the Drug Enforcement
Agency's ARCOS tracking system, or mortality data from National Vital Statistics System
(NVSS). However, scarcity of sources covering other topical areas may indicate a need for
additional data collection, such as addiction relapse or polydrug use, both of which have
been found to be pertinent to this public health problem [12], [15].
Limitations
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Much effort was made to conduct an exhaustive search for data sources and a
comprehensive examination of their relevance to prominent topics in the field. However, the
current work is subject to several limitations. First, the original list of keywords stemmed
from an existing library that was not created for the purpose of this project. Second,
although PubMed® is updated daily and has been identified as an optimal tool for electronic
searches [87], this search engine focuses primarily on medicine and biomedical sciences,
and may have excluded some relevant sources. Data sources may also have been
inadvertently excluded if their direct relevance to nonmedical opioid use was not discussed
in peer-reviewed academic literature. Third, the identification of prominent topics was
conducted subjectively by members of a larger research project which uses System
Dynamics to investigate the nonmedical use of pharmaceutical opioids in the United States.
Filtration and categorization of sources may also have been subject to human error.
Additional limitations to this work stem from its boundaries of inclusion. A specific focus
on nonmedical use of pharmaceutical opioids led to the exclusion of data sources regarding
medical use of pharmaceutical opioids for pain treatment as well as for treatment of
individuals exhibiting opioid or opiate abuse. These boundaries made the project much more
feasible, but preclude its usefulness for these related topics. Searches in PubMed were also
limited to the time period between January 1995 and April 2012.

Conclusions
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This work offers a systematic categorization of data sources pertaining to the nonmedical
use of pharmaceutical opioids in the United States. Data sources are categorized according
to their relevance to a number of prominent topics in the areas of diversion, nonmedical use,
and adverse outcomes associated with pharmaceutical opioids. Sources are also organized
according to their capacity for geographical and longitudinal trend analysis. This
categorization, provided in Tables 2 through 4, and the Appendix, can be used as a guide for
researchers, policy makers, and others who seek data regarding various aspects of this public
health problem. In addition, these tables show the distribution of data coverage across
topics, indicating which topics are covered by more and fewer sources. This work serves to
increase awareness of data sources that exist, suggests topics that may require additional
data collection, and is hoped to facilitate ongoing research, analysis, and evaluation of this
public health problem.
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Appendix
Appendix

Categorization of Data sources by ideographical and Longitudinal Design Attributes
TOPICS: Data
Sources By
Geographical And
Longitudinal
Design Attributes
Geographical
Trends in Opioid
Abuse

†
SCALE
National

State

Multi-center

□ ARCOS [62]

□ CDAS*[95], [30],
[31]
□ Insurance Claims
Data [117]

□ [96]

□ CDAS* [95], [30],
[31]
□ Insurance Claims
[79], [119]
□ Medical Examiners
[80]
□ [12]

□ RADARS® [120]

□ DAWN [82], [6]
□ MIT* [9]

Single-Center

□ NAVIPPRO [86], [57],
[90]
□ NIS [110], [78]
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□ NPDS [10], [84], [111],
[115]
□ NSDUH* [116]
□ NVSS [83], [97]
□ ThDS [98], [99]
□ VA Medical Records
[112]
‡
Longitudinal
Trends in Opioid
Abuse

□ ARCOS [62]
□ DAWN [82], [6], [89]
□ MIT* [9]
□ NAVIPPRO [86][57]

□ [121]

□ [13]

□ NESARC [91], [92]
□ NIS [110] [78]
□ NLAES [92]
□ NSDUH* [94] [3]
□ NVSS [83], [118]
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□ TEDS [98] [99]
□ VA Medical Records
[112]
□ [51]
Bold type font indicates a data source that is publicly available.
Acronyms Used: ARCOS (Automation of Reports and Consolidated Order System), CD AS (Center for Drug and Alcohol
Studies), DAWN (Drug Abuse Warning Network), MIT (Monitoring the Future), NAVIPPRO (National Addictions
Vigilance Intervention and Prevention Program), NESARC (National Epidemiologic Survey on Alcohol and Related
Conditions), NIS (Nationwide Inpatient Sample), NLAES (National Longitudinal Alcohol Epidemiology Survey), NPDS
(National Poison Data System), NSDUH (National Survey on Drug Use and Health), NVSS (National Vital Statistics
System), RADARS® (Researched Abuse, Diversion and Addiction-Related Surveillance), TEDS (Treatment Episode Data
Set), VA (Veterans Affairs)
*
Source measurement does not strictly limit responses to pharmaceutical opioids, but instead lists “pain killers,” “pain
medicine,” “pain relievers,” or “narcotics other than heroin”
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†

Scale categorization indicates the highest geographical scale at which the source is relevant. Many sources also have more
detailed information at smaller scales than are listed here.
‡
Longitudinal data sources include cohort or panel studies as well as `repeated cross sectional' studies.
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Clinical Question
This work offers a systematic categorization of data sources regarding the diversion,
nonmedical use, and adverse outcomes associated with pharmaceutical opioids in the
United States.
Type of Review
Systematic
Search of the Literature
Searches were conducted using PubMed®, with three sets of keywords:

NIH-PA Author Manuscript

1.

Opioid/Opioids, Misuse/Noncompliance/Non-Compliance/Diversion

2.

Opioid/Opioids, Deaths/Drug-Related Harm/Fatal Outcome/Mortality/
Overdose/Poisoning

3.

Opioid/Opioids, Abuse/Aberrant Drug-Related Behaviors/Addiction/Abuse
Liability/Problem Drug Use/Substance Use Disorders/ Substance-Related
Disorders/Substance Related Disorders/ Nonmedical Use/Non-Medical Use/
Non-Medical Use

All sources were categorized according to their relevance to each of 20 topics and 2
design features.
Conclusions
Tables cataloging data sources can be used to identify data relevant to specific topics in
diversion, nonmedical use, and adverse outcomes, and for their capacity for geographical
and longitudinal trend analysis. Global trends in coverage suggest that some topics have
been measured plentifully, while others only minimally. The importance of some topics
may warrant further data collection, including nonmedical use frequency, addiction
relapse, polydrug use, availability of pharmaceutical opioids for nonmedical use,
domestic impact, and transaction tracking.
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Limitations
Searches were conducted solely in PubMed®, and were restricted to peer-reviewed
academic journals. Keywords were identified through an existing collection of resources
from a separate research project which uses computer simulation to investigate the public
health problem of nonmedical opioid use. Identification of prominent topics was
conducted subjectively by members of this simulation research project. Filtration and
categorization of sources may also have been subject to human error.
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Figure 1.

Bi-Partite Network depicting Connections between Large Scale Sources and Topics
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Table 1

NIH-PA Author Manuscript

Opioid Searches Submitted to PubMed® in May 2012
Opioid Searches
(1) (Opioid OR Opioids) AND (Misuse OR Noncompliance OR “Non-compliance” OR Diversion) AND (“1995/01/01”[Date - Publication] :
“2012/05/01”[Date - Publication])
(2) (Opioid OR Opioids) AND (Deaths OR “Drug-related harm” OR “Fatal Outcome” OR Mortality OR Overdose OR Poisoning) AND
(“1995/01/01”[Date - Publication] : “2012/05/01”[Date - Publication])
(3) (Opioid OR Opioids) AND (Abuse OR “Aberrant drug-related behaviors” OR Addiction OR “Abuse Liability” OR “Problem Drug Use”
OR “Substance Use Disorders” OR “Substance-Related Disorders” OR “Substance related disorders” OR “Nonmedical Use” OR “Non-medical
Use” OR “Nonmedical Use") AND ("1995/01/01"[Date - Publication] : “2012/05/0l"[Date - Publication])
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Individual Characteristics of those exhibiting
Nonmedical Use

Initiation of Nonmedical Use

Frequency of Nonmedical Use

Prevalence of Nonmedical Use among NonPatients

Prevalence of Misuse/Abuse among Patients

TOPICS: Nonmedical Use

□ [96], [36]*, [13], [37],

□ [12]

□ MTF* [9], [39]

□ [12]

□ MTF* [9]

□ NVSS [83] [97]

□ NSDUH* [94], [7], [40], [41],
[46], [47], [68], [69], [70]

□ NLAES* [92]

□ NESARC* [92], [93]

□ NAVIPPRO [86], [57], [90]

□ CDAS*
[95], [30],
[31]

□ DAWN [82], [6]

□ NSDUH [94], [2], [41]

□ NAVIPPRO [86], [90]

□ NSDUH* [94], [40]

□ MTF* [39]

□ [51]

□ NSDUH* [94], [7], [41], [46]

□ NLAES* [92]

□ NESARC* [91], [92], [93]

□ RADARS® [50], [75]
□ [16], [48], [36]*, [32], [13], [34],
[37]

□ RADARS® [75]

□ [36]*

□ RADARS® [25], [75]

□ CDAS*
[95], [30],
[31]

□ DAWN [82], [6], [89]

□ NAVIPPRO [86], [57], [90]

□ [16], [32], [34]

□ [88]

Multi-center
□ RADARS® [25], [75]

State

†
SCALE

□ Toxicology [33]

National

Categorization of Data Sources Regarding the Nonmedical Use of Pharmaceutical Opioids

□ Treatment Centers [45], [100], [101]
□ [24], [58], [35], [15], [38], [38], [52], [17],
[42]

□ [42]

□ [26], [35], [38]

□ [44], [29], [24], [26], [35], [14], [38], [42]

Single-Center

NIH-PA Author Manuscript
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NIH-PA Author Manuscript

Rev Health Care.
□ NAVIPPRO [86], [90]

□ DAWN [82], [6]

□ NSDUH* [94] , [53], [54]
□ [13]

□ [29], [35], [59], [38], [15], [58], [42]

□ [38], [42]

□ [24], [66], [14], [38], [52]

□ [17]

Single-Center

Scale categorization indicates the highest geographical scale at which the source is relevant. Many sources also have more detailed information at smaller scales than are listed here.

†

Source measurement does not strictly limit responses to pharmaceutical opioids, but instead lists “pain killers,” “pain medicine,” “pain relievers,” or “narcotics other than heroin”

*

Acronyms Used: CDAS (Center for Drug and Alcohol Studies), DAWN (Drug Abuse Warning Network), MTF (Monitoring the Future), NAVIPPRO (National Addictions Vigilance Intervention and
Prevention Program), NESARC (National Epidemiologic Survey on Alcohol and Related Conditions), NLAES (National Longitudinal Alcohol Epidemiology Survey), NPDS (National Poison Data
System), NSDUH (National Survey on Drug Use and Health), NVSS (National Vital Statistics System), RADARS® (Researched Abuse, Diversion and Addiction-Related Surveillance), TEDS (Treatment
Episode Data Set)

Bold type font indicates a data source that is publicly available.

Prevalence of Polydrug Use

□ [48], [13], [37]

□ NAVIPPRO [86], [57], [90]
□ NPDS [10], [72], [84]

□ RADARS® [55]

□ [37]
□ MTF* [39]

□ RADARS® [102]

□ [36]*, [48]

□ RADARS® [50]

Routes of Administration

□ CDAS*
[95], [30],
[31]

□ MTF* [9]

□ [51]

□ MTF* [9]

□ NLAES* [92]

□ NESARC* [91], [92]

Multi-center

Motivations/Attitudes toward Nonmedical Use

Social Characteristics of those exhibiting
Nonmedical Use

□ Toxicology [33]

□ TEDS [98], [99]

State

NIH-PA Author Manuscript
National

†
SCALE

NIH-PA Author Manuscript

TOPICS: Nonmedical Use
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NIH-PA Author Manuscript

NIH-PA Author Manuscript

Rev Health Care.
□ [71]

□ NAVIPPRO [86], [57], [90]

□ [29], [14]

□ [18], [66]

□ Police Records [64]

Single-Center

Scale categorization indicates the highest geographical scale at which the source is relevant. Many sources also have more detailed information at smaller scales than are listed here.

†

Source measurement does not strictly limit responses to pharmaceutical opioids, but instead lists “pain killers,' “pain medicine,” “pain relievers,” or “narcotics other than heroin”

*

Acronyms Used: ARCOS (Automation of Reports and Consolidated Order System), CDAS (Center for Drug and Alcohol Studies), DAWN (Drug Abuse Warning Network), MTF (Monitoring the Future),
NAVIPPRO (National Addictions Vigilance Intervention and Prevention Program), NPDS (National Poison Data System), NSDUH (National Survey on Drug Use and Health), RADARS® (Researched
Abuse, Diversion and Addiction-Related Surveillance)

Bold type font indicates a data source that is publicly available.

□ NPDS [84], [10], [72]

□ RADARS® [73], [74], [75]

□ DAWN [82], [6]

□ [106] [71], [105]

□ [105], [37]

□ RADARS® [50], [65], [75]

□ RADARS® [65]

Multi-center

Prescription Drug Post-Marketing Surveillance

□ CDAS* [95], [30], [31]

□ CDAS* [95], [30], [31]

State

□ MTF* [9]

□ NSDUH* [94], [68], [70], [104]

□ NAVIPPRO [86], [57]

□ MTF* [39], [67]

□ ARCOS [103], [62], [63]

National

†
SCALE

Availability of Opioids

Sources of Prescription Drugs

Prescription Drug Diversion by Healthcare Workers

Controlled Substances Transactions/Tracking

TOPICS: Diversion

Categorization of Data Sources Regarding Diversion of Pharmaceutical Opioids
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NIH-PA Author Manuscript

NIH-PA Author Manuscript

Rev Health Care.
□ NPDS [84], [114]

□ NVSS [83], [112]

□[12]

□ Treatment Centers [85]
□ CDAS* [95], [30], [31]
□ Insurance Claims Data [79]

□ ACMT [77]

Multi-center

□ [26], [35], [38],

□ [17]

□ Medical Records [108]

□ Medical Records [108]

Single-Center

Scale categorization indicates the highest geographical scale at which the source is relevant. Many sources also have more detailed information at smaller scales than are listed here.

†

Source measurement does not strictly limit responses to pharmaceutical opioids, but instead lists “pain killers,' “pain medicine,” “pain relievers,” or “narcotics other than heroin”

*

Acronyms Used: ACMT (American College of Medical Toxicology), CDAS (Center for Drug and Alcohol Studies), DAWN (Drug Abuse Warning Network), NAVIPPRO (National Addictions Vigilance
Intervention and Prevention Program), NESARC (National Epidemiologic Survey on Alcohol and Related Conditions), NIS (Nationwide Inpatient Sample), NLAES (National Longitudinal Alcohol
Epidemiology Survey), NPDS (National Poison Data System), NSDUH (National Survey on Drug Use and Health), NVDRS (National Violent Death Reporting System), NVSS (National Vital Statistics
System), VA (Veterans Affairs)

Bold type font indicates a data source that is publicly available.

Domestic Impact

□ DAWN [82], [6]

Suicide, Violence, Violent Suicide
□ NVDRS [113]

□ NAVIPPRO [86], [57]

□ VA Medical Records [112]

□ NSDUH* [94], [40], [47], [68]

□ NLAES* [92]

□ NESARC* [91], [92], [93]

□ NAVIPPRO [86], [57], [90]

□ DAWN [82], [6]

□ NPDS [10], [72], [84], [111]

□ NIS [110], [78]

□ DAWN [82], [6], [109]
□ CDAS* [95], [30], [31]
□ Insurance Claims Data [79]

□ Medical Examiners [80], [81]

□ NPDS [10], [72], [84]
□ NVSS [83], [97], [107]

State

†
SCALE
National

Addiction Relapse

Prevalence of Substance Use Disorders

Prevalence of Opioid Poisoning (Nonfatal or Fatality Unspecified)

Prevalence of Fatal Opioid Poisoning

TOPICS: Adverse Outcomes

Categorization of Data Sources Regarding Adverse Outcomes Associated with Pharmaceutical Opioids
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